Jiangsu Recbio Technology gets Philippines FDA approval for comparative study between ReCOV and mRNA vaccines
Jiangsu Recbio Technology Co., Ltd. announced that the company has recently received the clinical trial approval for its recombinant protein Covid-19 vaccine, ReCOV (ReCOV) from the Food and Drug Administration (FDA) of the Philippines. The company to conduct a randomized, double-blind, active controlled phase II clinical trial of ReCOV on healthy subjects aged 18 years or above who have received primary vaccination with two doses of an inactivated Covid-19 vaccine to compare the immunogenicity and safety between ReCOV and Pfizer
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!